APA (7th ed.) Citation

Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R., . . . Camidge, D. R. (2016). Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. Lancet Oncology, 17(12), 1683. https://doi.org/10.1016/S1470-2045(16)30392-8

Chicago Style (17th ed.) Citation

Gettinger, Scott N., et al. "Activity and Safety of Brigatinib in ALK-rearranged Non-small-cell Lung Cancer and Other Malignancies: A Single-arm, Open-label, Phase 1/2 Trial." Lancet Oncology 17, no. 12 (2016): 1683. https://doi.org/10.1016/S1470-2045(16)30392-8.

MLA (9th ed.) Citation

Gettinger, Scott N., et al. "Activity and Safety of Brigatinib in ALK-rearranged Non-small-cell Lung Cancer and Other Malignancies: A Single-arm, Open-label, Phase 1/2 Trial." Lancet Oncology, vol. 17, no. 12, 2016, p. 1683, https://doi.org/10.1016/S1470-2045(16)30392-8.